Clinical Trial Update: Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLL [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluates frontline venetoclax-based therapy with obinutuzumab (VenObi) followed by venetoclax alone or with zanubrutinib (VenZan) as an MRD-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• BRUKINSA (ZANUBRUTINIB)
• Gazyva (Obinutuzumab)
• Venclyxto (Venetoclax)

Snippet

Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto | Conditions: High Risk CLL, Chronic Lymphocytic Leukemia | Phase 2 | Status: ACTIVE_NOT_RECRUITING